July 21, 2015

Tonix Pharmaceuticals Appoints Mark T. Edgar, PhD as Senior Vice President of Product Development

Company Bolsters Internal Expertise With Key Appointment to Newly-Created Position

NEW YORK, July 21, 2015 (GLOBE NEWSWIRE) --Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix"), a clinical-stage company developing next-generation medicines for fibromyalgia, post-traumatic stress disorder (PTSD), and episodic tension-type headache, has appointed Mark T. Edgar, PhD to the newly-created position of Senior Vice President of Product Development.

Dr. Edgar brings to Tonix over 25 years of experience in pharmaceutical development and commercialization. He has extensive expertise in advancing research-stage pharmaceutical candidates to commercialization, and has authored chemistry, manufacturing, and controls (CMC) strategies for numerous drug development programs. He joins Tonix from M.T. Edgar Consulting, where he provided pharmaceutical development support for over 46 companies, including Tonix, across a wide variety of formulations and therapeutic indications since founding the firm in 2003. From 1995 to 2003, Dr. Edgar held several executive level management positions in the biopharmaceutical industry, including Executive Vice President of Ancile Pharmaceuticals, Senior Vice President of Product Development of La Jolla Pharmaceutical Company, and Vice President of Development Research of Syntex Corporation, where he began his industry career as a research chemist.

Dr. Edgar commented, "I look forward to working even more closely with the Tonix team as we advance the company's candidates through Phase 3 registration studies in fibromyalgia as well as Phase 2 clinical trials in PTSD and episodic tension-type headache. I believe Tonix's pipeline offers transformative treatment potential in areas of significant unmet need."

"Mark brings extraordinary experience to this critical position as well as intimate knowledge of Tonix's programs, having worked side-by-side with us as a consultant for almost four years," said Seth Lederman, MD, chairman and CEO of Tonix. "His expertise and experience with our product candidates are a strong fit to support our objectives to advance our pipeline of critically needed product candidates to commercialization."

Dr. Edgar earned his PhD in organic chemistry from Arizona State University and conducted post-doctoral research at both Stanford University and the Universite de Scientifique et Medicale in Grenoble, France. He has authored several peer-reviewed scientific publications. Dr. Edgar also has an MBA from the University of Colorado at Boulder.

About Tonix Pharmaceuticals Holding Corp.

Tonix is dedicated to the development of next-generation medicines for common disorders of the central nervous system, characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and significant economic burden. Tonix's Tonmya™ is currently being evaluated in the Phase 3 AFFIRM study in fibromyalgia. TNX-102 SL, the same proprietary product candidate as Tonmya, is currently being evaluated in the Phase 2 AtEase study in post-traumatic stress disorder. A Phase 2 proof-of-concept study of TNX-201 in episodic tension-type headache is ongoing. This press release and further information about Tonix can be found at www.tonixpharma.com.

Safe Harbor / Forward-Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our possible need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K filed with the SEC on February 27, 2015 and future periodic reports filed with the Securities and Exchange Commission. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof.

CONTACT: Tonix Pharmaceuticals Holding Corp.
Leland Gershell
Chief Financial Officer
(212) 980-9155 x104
leland.gershell@tonixpharma.com

Investor Relations
Martini Communications
Amy Martini
amartini@martinicommunications.com

Public Relations
Dian Griesel Int'l.
Susan Forman / Laura Radocaj
(212) 825-3210
sforman@dgicomm.com
lradocaj@dgicomm.com

Source: Tonix Pharmaceuticals Holding Corp.